Perimenopause — the transition phase before menopause — typically begins in the mid-40s and can last up to a decade. During this time, fluctuating and declining estrogen levels drive weight gain, particularly around the abdomen, while making existing weight harder than ever to lose.
GLP-1 medications directly counter several of the mechanisms driving perimenopausal weight gain. They improve insulin sensitivity, reduce visceral fat specifically, dampen food noise, and support steadier blood sugar — all of which are particularly beneficial during this phase.
Some women report fewer and less severe hot flashes as they lose weight on GLP-1 — likely because excess adipose tissue worsens thermoregulation and inflammation. This is not a guaranteed effect, but it's a commonly reported bonus.
Rapid weight loss during perimenopause warrants attention to bone density, since estrogen protects bones and both declining estrogen and significant caloric restriction can reduce bone mineral density. Ensure adequate calcium (1200 mg/day) and vitamin D (800–2000 IU/day), and discuss DEXA scans with your doctor.
Many women use GLP-1 alongside menopausal hormone therapy (MHT). There are no known major interactions. Some evidence suggests MHT may enhance the metabolic benefits of GLP-1 in this population — an active area of research.
Getting 100g+ of protein daily on a reduced appetite is hard. Strategic timing makes it more achievable — and more effective for muscle preservation.
Medication helps with appetite. But the mental skills for sustainable weight management — resilience, flexibility, self-compassion — must be built intentionally.
People who share their journey with a community — online or in person — consistently achieve better outcomes. Here's why, and where to find yours.